Percentage of People on GLP-1: What the UK Data Can and Cannot Tell You (October 2026)

01 · The core answer

So what percentage of people are on GLP-1?

The honest answer is that nobody can give you one trustworthy number for the whole UK population. Some figures count only adults who say they are currently injecting for weight loss. Others count anyone who has ever tried a GLP-1 medicine. Others add people prescribed these drugs for diabetes. These are three different questions, so they produce three different answers, and the gaps between them are not errors.

Online surveys add another wrinkle. They reach people who choose to respond, and they rely on self-reporting, so people may mislabel what they take. Prescribing data is more reliable, but it does not capture private prescriptions, which many UK adults use.

Use has grown considerably, the medicines are now widely discussed, and a rising share of that use is through regulated online pharmacies as well as NHS services. For related reading, see our guides on how many people are using GLP-1 medicines and what share of people use weight loss drugs.

02 · Your decision

Is this relevant to you, and what next?

For most readers the real question is not how many others use these drugs but whether treatment suits them. The licensed criteria for Mounjaro depend on BMI and weight-related health conditions, and the NHS has its own, stricter, phased access. Mounjaro is available on the NHS, but access is being phased in over several years.⁵ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶

If you are weighing up whether to start, the useful checks are practical. Do you have a BMI of 30 or above, or 27 with a weight-related condition? Are you ready to pair medication with a reduced-calorie diet and more activity? Can you commit to follow-up reviews? A prescriber, not a survey, decides whether it is right for you.

The ordering route is simple. You complete a free online consultation, a GPhC-registered prescriber reviews it, and if approved your pen is dispensed and sent by free next-day tracked delivery, with same-day dispatch when ordered by 3pm. A starter 2.5mg pen is £169.99 at the standard price, and new customers save £40 on their first order with code FIRST40. You can read the details on the Mounjaro pen page, or browse our weight loss clinic for the wider picture. Doses are in stock as of October 2026.

If you are not ready, that is fine. Treatment is a prescription decision for you and a clinician, not a trend to follow because others are doing it.

03 · Why figures differ

Why every survey gives a different percentage

Every published percentage answers a slightly different question, so comparing them directly is a mistake. The main differences are who was asked, what time period was covered, and which medicines and reasons for use were counted. Once you check those three things, most apparent contradictions disappear.

First, the group. A poll of adults who are already trying to lose weight will show far higher use than a poll of the whole population including children, older adults and people with no weight concerns. A figure quoted as a share of the population is therefore not comparable with a share of people living with obesity. Neither is wrong, but they are not interchangeable.

Second, the time frame. Current use means injecting now. Ever-use includes people who tried a medicine briefly and stopped. Because many people stop for reasons such as cost, side effects, or reaching a goal, ever-use is always larger than current use. Headlines that blur the two can make uptake look either bigger or smaller than it is.

Third, the scope. GLP-1 medicines are used for diabetes, for weight management and, in some cases, for other conditions. A survey that includes all prescribing will report more users than one that asks only about weight loss. Brand matters too: some surveys name Ozempic, Wegovy and Mounjaro, others use the generic class, and respondents often confuse brands. Tirzepatide, the active ingredient in Mounjaro, acts on GLP-1 and a second hormone receptor, so even the class label is not always applied the same way.¹

Finally, the method. Self-reported online surveys depend on who chooses to respond and can be skewed by interest in the topic. Prescribing databases are firmer but often miss private prescriptions. Sales data counts packs, not people, since one person may use many pens over time.

The practical lesson is to read the small print before you share or rely on any number. Look for the sample, the question wording and the date. If a statistic does not tell you those, treat it as a rough indicator at best. If you want to see how the same cautious approach applies to one medicine, read our guide to how many people are taking Mounjaro.

None of this means usage is trivial. It means the right takeaway is direction, not precision: use has risen markedly, it is concentrated among adults living with overweight or obesity, and it is spread across NHS and private routes in ways that no single dataset fully captures.

04 · UK versus US figures

Why US survey numbers do not describe the UK

The two countries differ in how medicines are prescribed, paid for, advertised and regulated, so uptake patterns diverge even when the same drugs are involved.

In the US, direct-to-consumer advertising, employer insurance and a much larger private market all shape who gets a prescription. In the UK, the NHS is the default route for most prescribing, and access to weight-management injections is deliberately phased. That means a share of people who would qualify clinically are not yet reachable through the NHS, and some use private regulated services instead.

On the NHS side, access depends on eligibility rules that tighten who is seen first. Mounjaro is available on the NHS, but access is being phased in over several years.⁴ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

That has a direct effect on any UK percentage. A count based only on NHS records will understate total use because private prescribing sits outside it. A count based on online polls may overstate it if respondents are enthusiastic. Neither can be treated as the full picture, and an honest UK figure needs both pieces, which is not currently published in one place.

Cultural factors differ as well. Public conversation in the US is heavily driven by celebrity and media coverage, which can inflate the sense of how common use is. In the UK the conversation is more tied to NHS waiting, cost, and debates about access. Both shape what people report in surveys.

If you are reading a US number and wondering whether it applies to you, the safest assumption is that it does not. Use it only as a sign that the medicines are widely discussed. For decisions about your own care, the relevant facts are your BMI, your health conditions, your goals, and what a prescriber advises.

You may also find our page on the share of people on weight loss drugs helpful.

05 · NHS and private routes

NHS and private prescribing: who ends up on treatment

People reach GLP-1 treatment through three broad routes: NHS diabetes care, NHS weight-management services, and regulated private providers. Each is counted differently, which is one reason a single percentage is so hard to produce.

On the NHS, prescribing for diabetes has a long history and is recorded within general practice data. Weight-management prescribing is newer and rolling out in stages. Mounjaro is available on the NHS, but access is being phased in over several years.⁵ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

For Wegovy, NHS access runs through specialist weight-management services; ask your GP about local arrangements.

Private treatment through a registered pharmacy follows a similar clinical logic but a different pathway. At EverydayMeds, a GPhC-registered pharmacy (registration GPhC 9012878), the steps are a free online consultation, a review by a GPhC-registered prescriber, dispensing by our registered pharmacy, and free next-day tracked delivery in temperature-controlled packaging. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Repeat orders re-check suitability, so there is no auto-shipping.

Why does this matter for the percentage? Because the people on private treatment do not appear in NHS prescribing counts. Any figure built solely from NHS data will therefore undercount real-world use. Conversely, a figure built from a poll of people who buy online might overstate the national picture, since it draws from a self-selected group.

There is also movement between routes. Some people start privately and later move to NHS care when they become eligible, and others the reverse. Counting people at a single moment misses that flow, so a snapshot percentage can hide how fluid the real situation is.

If you are deciding which route fits, the key differences are speed, eligibility and cost. The NHS route has stricter criteria and a phased timeline, while the private route follows the licensed criteria and is paid for by you. Current prices are shown on the Mounjaro product page, with a standard 2.5mg pen at £169.99 and a first-order discount available with code FIRST40. Whichever route you take, treatment sits alongside a reduced-calorie diet and increased physical activity.

06 · Who it does not work for

What percentage of people does GLP-1 not work for?

Rather than a single failure rate, clinicians look at response against a clear threshold.

That threshold is built into the way Mounjaro is reviewed. Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.⁴

The trial picture helps put this in context. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight.²

Those figures show that a large majority reached the lowest meaningful threshold in the trial, but they do not tell you what will happen to you. Trial participants were supported and followed closely, and real-world results can differ.

Slow early progress is not the same as failure. Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month. Three months in, most people are still on the lower rungs of the dose ladder, and slower early progress does not predict failure, because the dose you respond to may still be ahead of you.

Plateaus are also normal. Weight loss is not linear, and plateaus of a few weeks are expected as the body adapts to a lower weight. Sensible responses are to review food intake honestly, protect protein and activity, check sleep and alcohol, and ask your prescriber whether a dose step-up is appropriate. A plateau is not a reason to double doses or add unlicensed products.

For a deeper look at this question see our pages on whether GLP-1 fails for some people and how often Mounjaro does not work.

07 · Side effects and getting sick

What percentage of people get sick on GLP-1?

Gastrointestinal side effects are the most common problem on GLP-1 medicines, and many people experience some, but most are mild and tend to settle.

In STEP 1, gastrointestinal side effects were reported by 74.2% of people on semaglutide 2.4mg, compared with 47.9% on placebo.⁹ 7.0% stopped treatment because of side effects, compared with 3.1% on placebo.⁹ That tells you two things: such effects are frequent, but most people who have them continue treatment. These figures relate to semaglutide and should not be read across to other medicines as a comparison.

Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle. Experiences differ widely: some people notice appetite change early, others feel little until a higher dose, and both are normal.

The dose ladder is designed to ease this. If a new dose is hard to tolerate, prescribers can hold the current dose longer before stepping up, so speak to your clinical team rather than pushing through severe symptoms.

If something feels more than mild, speak to your prescriber rather than waiting it out. At EverydayMeds, ongoing monthly reviews, dose-titration and follow-up assessments by the prescribing team are part of the service, along with side-effect support by email, account chat or phone, Monday to Friday during office hours.

Report suspected side effects through the MHRA Yellow Card scheme, which helps regulators monitor safety.¹⁹ The patient information leaflet lists the full range of effects and the warning signs that need urgent attention, and it is worth reading before your first dose.¹³

You will also see online discussion of rarer concerns, such as pancreatitis. We cover that separately in our page on pancreatitis and GLP-1 medicines. As with all side effects, a number from one trial does not predict your own experience. Severe or persistent stomach pain needs medical help straight away.

08 · Why use has grown

How are so many people on GLP-1?

Use has grown because these medicines produce larger average weight loss than earlier options, they are given as a simple once-weekly injection, and awareness has risen sharply. Understanding the mechanism explains much of the appeal.

Tirzepatide, the active ingredient in Mounjaro, is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic).

The results explain the attention. In SURMOUNT-1, average weight loss built month by month, with the full 15–21% averages measured at 72 weeks, not 12.² Trial work also found average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels. These are trial-average secondary outcomes, not promises, but they are why prescribers talk about weight management as health management rather than appearance.

In a direct comparison, SURMOUNT-5 found that average loss was 22.8 kg vs 15.0 kg for tirzepatide against semaglutide 2.4mg over 72 weeks.¹⁵ That is a head-to-head result and it is one reason clinicians and patients pay close attention to the newer medicine.

Access has widened too. NICE has recommended tirzepatide for eligible adults, and the NHS has begun a phased rollout.⁴ At the same time, regulated online pharmacies have made private treatment easier to reach for people who meet the licensed criteria, with consultations done online rather than in a clinic.

Social and media attention has also played a part. High-profile coverage and public conversation have made people more willing to discuss weight and medical treatment, which in turn raises the number who ask a prescriber about it. That attention can inflate perceptions of how common use is, which is another reason to treat casual claims, including about celebrities, with caution.

None of this means the medicines suit everyone. They are prescription-only, used alongside a reduced-calorie diet and increased physical activity, and individual results vary. Growth in use reflects availability and interest as much as individual suitability, so your decision should rest on your own health and a prescriber's advice. Our guide on how many people are on Mounjaro goes into this one medicine in more detail.

09 · Downsides and safest option

Downsides, risks and the safest GLP-1

The main downsides are gastrointestinal side effects, the need to keep taking treatment to keep the benefit, cost on the private route, and the fact that results vary. There is no honest way to name a single safest GLP-1, because safety depends on the person, the dose and the prescriber's assessment.

All the licensed medicines are prescription-only for good reason. A prescriber checks your health history, current medicines and suitability before supplying anything. Mounjaro (tirzepatide) is supplied only after an online consultation reviewed by a GPhC-registered prescriber, and it is used alongside a reduced-calorie diet and increased physical activity. Individual results vary.

In SURMOUNT-5, 751 adults took tirzepatide or semaglutide 2.4mg for 72 weeks.¹⁵ At least 10% of body weight was lost by 81.6% on tirzepatide vs 60.5% on semaglutide; at least 15% by 64.6% vs 40.1%; at least 20% by 48.4% vs 27.3%; at least 25% by 31.6% vs 16.1%.¹⁵ That addresses effectiveness. It does not rank safety, and a more effective option is not automatically a better fit for you.

Other safety points matter in practice. Mounjaro can reduce absorption of oral contraceptives because stomach emptying slows, so ask your prescriber about contraception. The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ If you take insulin or sulfonylureas, doses may need adjusting because of low blood sugar risk. Regulators have looked specifically at whether GLP-1 medicines are linked to low mood or suicidal thoughts: the EMA's safety committee concluded in 2024 that the evidence does not support a causal link, and the MHRA keeps this under continuous review.¹⁷ Tell your prescriber about any change in mood.

If you have thoughts of harming yourself or ending your life, get help straight away. Call 999 or go to A&E if you are in immediate danger. In England you can call NHS 111 and choose the mental health option, any time. You can also call Samaritans free on 116 123, day or night. Tell your prescriber about any change in your mood while taking Mounjaro.

Counterfeit products are a real hazard. Only buy from a registered pharmacy and check the register. Anyone offering to supply without a consultation or prescription should be avoided, and suspect products can be reported through the MHRA.⁷

Finally, report any suspected side effect through the Yellow Card scheme.¹⁹ A prescriber can talk through which licensed medicine suits your history rather than relying on a general ranking.

10 · Long-term use and stopping

Long-term use: how long, and what happens if you stop

How long someone stays on a GLP-1 medicine is an individual decision made with a prescriber, and there is no universal limit that makes a given duration too long. What matters is ongoing benefit, tolerability and continued suitability, which are reviewed at regular intervals.

Trials measured results at 72 weeks, so the headline figures describe that kind of timeframe, but real-world use often continues beyond a trial. Think in months, not days, and judge progress by trend, not individual weigh-ins. Early loss includes water weight, so single readings can mislead.

Reviews are built into care. If you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.⁴ On the other side, people who respond well and reach a stable weight can discuss maintenance with their prescriber.

When treatment stops, the medicine does not vanish at once. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system.¹ There is no way to speed this up, and nothing needs doing while it clears. Mounjaro manages weight; it does not cure the biology behind it. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.

Many surveys report that large numbers of people stop treatment, and that is one more reason current-use percentages sit well below ever-use ones. People stop for many reasons: cost, side effects, reaching their goal, or a change in health. A discontinuation headline does not by itself show that a medicine failed, because the reasons are mixed.

If you are thinking about stopping or changing dose, speak to your prescriber rather than adjusting alone. Practical help is available: our team provides ongoing monthly reviews, dose-titration and follow-up assessments, and the GLPTrackr companion app can help you log your journey on iOS or Android.

Treatment is a medical decision and should stay one.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹